8-K: PacBio Q3 2025: Revenue Down, Margins Up, New Chemistry

PacBio reported a slight revenue decline in Q3 2025 but achieved record consumable revenue, expanded gross margins, and introduced new sequencing chemistry.

Summary

• Total revenue for Q3 2025 was $38.4 million, a decrease from $40.0 million in Q3 2024.
• Consumable revenue reached an all-time record of $21.3 million in Q3 2025, up from $18.5 million in Q3 2024.
• Instrument revenue declined to $11.3 million in Q3 2025 from $16.8 million in Q3 2024, with 13 Revio systems shipped compared to 22 in Q3 2024.
• Non-GAAP gross margin expanded to 42% in Q3 2025, up from 33% in Q3 2024.
• GAAP net loss improved to $38.0 million in Q3 2025 from $60.7 million in Q3 2024.
• Non-GAAP operating expenses decreased to $53.9 million in Q3 2025 from $62.4 million in Q3 2024.
• Cash, cash equivalents, and investments stood at $298.7 million as of September 30, 2025, down from $471.1 million in Q3 2024.
• PacBio unveiled new SPRQ-Nx sequencing chemistry and consumables, projected to reduce sequencing costs by up to 40% and enable high-accuracy long-read genomes for under $300 at scale.
• The Sequel II CNDx system received Class III Medical Device Registration approval in China through partner Berry Genomics.
• The company launched an expanded PureTarget portfolio of long-read HiFi assays for carrier screening, supporting throughput for up to approximately 100,000 samples per Revio system annually.
• PacBio HiFi sequencing was selected for the National Institute on Aging's Long Life Family Study (up to 7,800 whole genomes) and the Korean Pangenome Reference Project (over 1,000 genomes).

Sentiment

Score: 5

Explanation: While revenue and instrument sales were below expectations and cash reserves significantly decreased, the company achieved record consumable revenue, improved gross margins, and reduced operating expenses. The introduction of new chemistry and key market approvals/project selections provide a positive long-term outlook, but current financial performance shows challenges.

Positives

• Achieved an all-time record for consumable revenue at $21.3 million, up from $18.5 million in Q3 2024.
• Non-GAAP gross margin expanded significantly to 42% in Q3 2025 from 33% in Q3 2024.
• GAAP net loss improved to $38.0 million in Q3 2025, compared to $60.7 million in Q3 2024.
• Non-GAAP net loss improved to $36.8 million in Q3 2025, compared to $46.0 million in Q3 2024.
• Operating expenses were reduced, with GAAP operating expenses totaling $54.8 million and non-GAAP operating expenses totaling $53.9 million in Q3 2025, down from $74.1 million and $62.4 million respectively in Q3 2024.
• Introduced SPRQ-Nx sequencing chemistry, expected to reduce sequencing costs by up to 40% and enable high-accuracy long-read genomes for under $300 per genome at scale.
• The Sequel II CNDx system received Class III Medical Device Registration approval in China, expanding market access.
• Launched an expanded PureTarget portfolio of long-read HiFi assays, enhancing capabilities for carrier screening.
• PacBio's HiFi sequencing was selected for significant research initiatives, including the National Institute on Aging's Long Life Family Study and the Korean Pangenome Reference Project.

Negatives

• Total revenue of $38.4 million for Q3 2025 was slightly below expectations and decreased from $40.0 million in Q3 2024.
• Instrument revenue declined to $11.3 million in Q3 2025 from $16.8 million in Q3 2024.
• The number of Revio systems shipped decreased to 13 in Q3 2025 from 22 in Q3 2024.
• Annualized Revio pull-through per system decreased to approximately $236,000 in Q3 2025 from approximately $255,000 in Q3 2024.
• Cash, cash equivalents, and investments significantly decreased to $298.7 million as of September 30, 2025, from $471.1 million in Q3 2024.

Risks

• Challenges inherent in developing, manufacturing, launching, marketing, and selling new products, and achieving anticipated new sales.
• Potential cancellation of existing instrument orders.
• Uncertainties related to the ability to attract new customers and retain and grow sales from existing customers.
• Risks related to the ability to successfully execute and realize the benefits of acquisitions.
• The impact of new, increased, or enhanced tariffs and export restrictions.
• Rapidly changing technologies and extensive competition in genomic sequencing.
• Unanticipated increases in costs or expenses.
• Interruptions or delays in the supply of components or materials for, or manufacturing of, products and products under development.
• Potential product performance and quality issues and potential delays in development timelines.
• The possible loss of key employees, customers, or suppliers.
• Customers and prospective customers curtailing or suspending activities using products.
• Third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate patents or proprietary rights.
• Risks associated with international operations.
• Other risks associated with general macroeconomic conditions and geopolitical instability.

Future Outlook

PacBio expects the newly introduced SPRQ-Nx chemistry to dramatically lower the cost of human genome sequencing, making their technology economically competitive with many short-read sequencing platforms. The company is focused on disciplined growth and making its highly accurate long-read sequencing more accessible worldwide.

Management Comments

• "While revenue came in slightly below our expectations this quarter, we achieved another all-time record for consumable revenue, expanded gross margins and continued to reduce our operating expenses."
• "We also reached an important milestone on our technology roadmap with the introduction of SPRQ-Nx chemistry, which we believe will help dramatically lower the cost of human genome sequencing and make our technology economically competitive with many short read sequencing platforms."
• "These achievements underscore our focus on disciplined growth and our commitment to making PacBios highly accurate long-read sequencing more accessible worldwide."

Industry Context

The introduction of SPRQ-Nx chemistry, aiming for sub-$300 genomes, positions PacBio to compete more directly with short-read sequencing platforms on cost, a critical factor for broader adoption in genomics. The approvals and project selections (China, National Institute on Aging, Korean Pangenome) indicate growing acceptance and demand for long-read sequencing in clinical research and large-scale genomic initiatives, aligning with a broader industry trend towards more comprehensive genomic understanding.

Comparison to Industry Standards

• The goal of 'under $300 per genome at scale' with SPRQ-Nx chemistry directly addresses the cost competitiveness with short-read sequencing platforms, which have historically dominated large-scale projects due to lower per-base costs. This could make HiFi sequencing a more viable option for projects that previously opted for short-read due to budget constraints.
• The Class III Medical Device Registration approval for the Sequel II CNDx system in China, through Berry Genomics, indicates a significant step in market penetration and regulatory acceptance in a key global market, comparable to other major genomics companies seeking similar approvals for diagnostic use.
• The selection of Revio for the National Institute on Aging's Long Life Family Study (7,800 whole genomes) and HiFi sequencing for the Korean Pangenome Reference Project (>1,000 genomes) demonstrates PacBio's technology being adopted for large-scale, high-profile genomic initiatives, similar to how Illumina's platforms have been used in large population genomics projects globally.

Stakeholder Impact

• Shareholders: Mixed impact. Revenue decline and cash burn are concerning, but improved margins, reduced operating expenses, and strategic product developments (SPRQ-Nx, China approval) could signal future growth and efficiency. The stock price may react negatively to the revenue miss but positively to the strategic advancements.
• Customers: Positive impact from new SPRQ-Nx chemistry offering lower sequencing costs and expanded PureTarget portfolio. Increased accessibility and utility of HiFi sequencing.
• Employees: Restructuring costs mentioned in the non-GAAP reconciliation tables (related to 2025 and 2024 plans) could imply past or ongoing workforce adjustments.

Next Steps

• Continue focus on disciplined growth.
• Make highly accurate long-read sequencing more accessible worldwide.
• Further development and adoption of SPRQ-Nx chemistry to lower sequencing costs.
• Management will host a quarterly conference call on November 5, 2025, at 4:30 p.m. Eastern Time to review financial results.

Key Dates

Recommendation

The company presents a mixed financial picture with declining total revenue and significant cash burn, which are negative indicators. However, the growth in consumable revenue, improved gross margins, and substantial reduction in operating expenses demonstrate operational improvements. Crucially, the introduction of SPRQ-Nx chemistry and strategic market wins (China approval, major project selections) offer strong long-term potential by addressing cost barriers and expanding market reach for long-read sequencing. Given the current financial challenges balanced against promising strategic developments, a 'hold' recommendation is appropriate, suggesting investors monitor the execution of new product strategies and future financial performance for clearer direction.

Keywords

genomic sequencing, long-read sequencing, HiFi sequencing, PacBio, PACB, Q3 2025 earnings, financial results, biotechnology, life science technology, DNA sequencing, SPRQ-Nx, Revio, consumable revenue, gross margin, operating expenses, net loss, China medical device approval, carrier screening, pangenome project